Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Holdings in Insmed, Inc. $INSM

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Insmed, Inc. (NASDAQ:INSM) by 35.3% in the first quarter, Holdings Channel reports. The fund owned 68,350 shares of the biopharmaceutical company’s stock after purchasing an additional 17,850 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Insmed were worth $11,177,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC increased its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the last quarter. Kingsview Wealth Management LLC raised its position in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 60 shares during the period. Choreo LLC raised its position in Insmed by 2.9% during the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Insmed by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 69 shares during the last quarter. Finally, ORG Partners LLC lifted its stake in shares of Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 74 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays boosted their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. Raymond James Financial assumed coverage on Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target for the company. Leerink Partners raised their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 24th. Bank of America lifted their price objective on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $211.86.

Insiders Place Their Bets

In related news, CEO William Lewis sold 21,398 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the completion of the transaction, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. The trade was a 7.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the transaction, the insider directly owned 37,648 shares in the company, valued at $3,607,431.36. This trade represents a 4.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,289 shares of company stock valued at $7,824,301 over the last quarter. 2.10% of the stock is currently owned by insiders.

Insmed Price Performance

Shares of NASDAQ INSM opened at $111.60 on Friday. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The firm has a 50-day simple moving average of $109.42 and a two-hundred day simple moving average of $140.81. The company has a market cap of $24.19 billion, a P/E ratio of -19.41 and a beta of 0.78. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s quarterly revenue was up 229.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.42) earnings per share. Research analysts anticipate that Insmed, Inc. will post -2.55 earnings per share for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.